

MYRIAD GENETICS INC  
Form 8-K  
March 01, 2005

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 1, 2005**

**MYRIAD GENETICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**0-26642**  
(Commission File Number)

**87-0494517**  
(IRS Employer Identification No.)

**320 Wakara Way**

**Salt Lake City, Utah 84108**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(801) 584-3600**

**Not Applicable**

(Former name or former address, if changed since last report)

## Edgar Filing: MYRIAD GENETICS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01 Other Events**

On March 1, 2005, Myriad Genetics, Inc. announced that it submitted an Investigational New Drug (IND) application to the FDA to begin a second Phase I human clinical trial with MPC-6827 to evaluate the potential of MPC-6827 to treat metastatic brain cancer. The press release is attached hereto as an exhibit to this Current Report on Form 8-K and is being filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K.

**ITEM 9.01 Financial Statements and Exhibits.**

(c) The following exhibit is filed with this report:

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	The Registrant's press release dated March 1, 2005.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MYRIAD GENETICS, INC.**

Date: March 1, 2005

By: /s/ Peter D. Meldrum  
Peter D. Meldrum  
President and Chief Executive Officer

EXHIBIT INDEX

**Exhibit**

**Number**

**Description**

99.1 The Registrant's press release dated March 1, 2005.

4

---